Health Kick Podcast: How Arovella is bringing hope with off-the-shelf cell therapy

Stockhead’s health and biotech expert Tim Boreham is back in the studio for another instalment of the Health Kick Podcast.

In this episode, Tim chats with Arovella Therapeutics (ASX:ALA) CEO and managing director Michael Baker.

The cancer immunotherapy space has been a hub of activity in recent year, with many biotechs investing lots of money into developing CAR-T therapies, a type of immunotherapy that re-engineers a patient’s own T cells to target and destroy cancer cells.

Arovella is focused on a sub set of CAR-Ts with its unique iNKT cell therapy platform to treat cancer.

This will help to create an off-the-shelf product to improve patient access to cell therapies.

Tune in to this episode to hear all about the work the company is doing and its innovation candidates.

This podcast was developed in collaboration with Arovella Therapeutics, a Stockhead advertiser at the time of publishing.

The interviews and discussions in this podcast are opinions only and not financial or investment advice. Listeners should obtain independent advice based on their own circumstances before making any financial decisions.